An innovative development by CannaMore of a CBD based solution for treatments of Bronchiolitis obliterans (BOS), a pulmonary inflammatory disease characterized obstruction of the lung's tiniest airways, called bronchioles. BOS is caused by various conditions including complications following a bone marrow or heart-lung transplant and more.
Based on a unique collaboration between CannaMore and BioSeedXL, NeuroSeed develops an innovative solution to treat the unmet need of Peripheral Neuropathy, a conditions that results from the nerves carrying the signals from the Central Nervous System to the Peripheral Nervous System are damaged or diseased from a wide range of conditions.
As an innovation under CannaMore, IcBD develops a patent-pended, novel, CBD-based enema formulation for the treatments of Inflammatory Bowel Diseases (IBD). Based on in-vivo, pre-clinical and clinical studies observations, IcBD plans to commence phase 2a clinical trials, starting with Ulcerative colitis on 2020 on the drug development in FDA route